David Spaight has served as a Certara director since 2022 as an Arsenal Capital Partners designee and sits on the Compensation Committee. He has been an Operating Partner at Arsenal Capital Partners since 2016 and previously served as Chairman and CEO of contract research organization WIL Research from 2010 to 2016 and as President of MDS Pharma Services. He has held executive roles at Fisher Scientific and PerkinElmer, chaired the Association of Clinical Research Organizations, and holds a B.S. and an MBA from the University of Michigan.